Author:
Mazin Abdulridha Ateyah ,Manal Khalid Abdulridha ,Munaim Jumaa Alkabee
Abstract
Background Saw palmetto contains powerful anti-inflammatory components commonly used in Benign prostatic hyperplasia (BPH) patients with symptoms. The current study was designed to assess the effectiveness of saw palmetto alone or supplementation
therapy with tamsulosin via measurement of some inflammatory biomarker in male with lower urinary tract symptoms (LUTS) consistent with (BPH).
Methods The present study is an interventional prospective randomized enrolled newly diagnosed patients with moderate to severe symptomatic BPH. The eligible 60 patients were allocated into (3) groups, each group with (20) patients; Group (1) treated with Saw palmetto cap (320 mg); Group (2) treated with Saw palmetto cap (320 mg) and tamsulosin (0.4mg); Group (3) treated with tamsulosin (0.4mg), protocols to be given once daily for 12 weeks. Measurement of prostate specific antigen (PSA), C-reactive protein (CRP), and interleukin 6 (IL-6) was done.
Results There was significant decrease in the serum PSA, CRP and IL-6 level (P<0.01) in group1 and 2 patients only after treatment when compared to pretreatment. Patients on combination therapy presented with high percent of change compared to other groups. No change in CRP and IL-6 level in patients on tamsulosin alone.
Conclusion From the findings of the present study, phytotherapy with Saw Palmetto alone or as supplement produced significant 3 months drop in both inflammatory markers, the total CRP level and IL-6 level. Also produced significant decrease in PSA level, and may substitute the conventional therapy in mild disease status.
Publisher
Al Mustansiriyah University - College of Pharmacy
Reference35 articles.
1. - Gravas S, Cornu JN, Drake MJ, Gacci M, Gratzke C, Herrmann TRW, Management of non-neurogenic male lower urinary tract symptoms (LUTS).2018: 2588-817X.
2. - Claus G Roehrborn, MD, FACS, Benign Prostatic Hyperplasia: An Overview2005; 7(Suppl 9): S3–S14.
3. - Chughtai, B. et al. ‘Benign prostatic hyperplasia’, Nature Reviews Disease Primers. Nature Publishing Group. 2016 May 5; 2:16031.
4. - Lim KB. Epidemiology of clinical benign prostatic hyperplasia. Asian journal of urology. 2017 Jul 1;4(3):148-51.
5. - Bosch JR, Bangma CH, Groeneveld FP, Bohnen AM. The long-term relationship between a real change in prostate volume and a significant change in lower urinary tract symptom severity in population-based men: the Krimpen study. European urology. 2008 Apr 1;53(4):819-27.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献